Stock Track | Erasca Plunges 30.08% in Overnight Trading Following Patent Infringement Allegations by Revolution Medicines

Stock Track

Apr 28

Erasca, Inc. (ERAS) experienced a dramatic 30.08% decline in overnight trading, as the clinical-stage oncology company faces serious legal challenges from competitor Revolution Medicines. The steep selloff was triggered by allegations that Erasca's development of its lead cancer drug, ERAS-0015, infringes on existing patents and relies on stolen trade secrets.

According to regulatory filings and news reports, Revolution Medicines sent Erasca a legal letter alleging that ERAS-0015 is "substantially equivalent" to one of its patented treatments. The competitor also claimed that a third party had misappropriated its trade secrets related to the patent involving ERAS-0015, and that Erasca is liable as a licensee under trade secret laws. Revolution Medicines has demanded that Erasca cease producing and selling ERAS-0015 in the United States.

While Erasca has stated it believes the assertions are without merit and intends to contest them vigorously, the allegations introduce significant uncertainty about the future of the company's key pipeline asset. The legal challenge overshadowed positive preliminary Phase 1 data that Erasca recently reported for ERAS-0015 in patients with RAS-mutant solid tumors, including lung and pancreatic cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1177486383"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177486383\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177486383?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-28 15:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177486383","market":"nz","top_or_hot":-1,"title":"Stock Track | Erasca Plunges 30.08% in Overnight Trading Following Patent Infringement Allegations by Revolution Medicines","media":"Stock Track","content":"<p>Erasca, Inc. (ERAS) experienced a dramatic 30.08% decline in overnight trading, as the clinical-stage oncology company faces serious legal challenges from competitor Revolution Medicines. The steep selloff was triggered by allegations that Erasca's development of its lead cancer drug, ERAS-0015, infringes on existing patents and relies on stolen trade secrets.</p><p>According to regulatory filings and news reports, Revolution Medicines sent Erasca a legal letter alleging that ERAS-0015 is \"substantially equivalent\" to one of its patented treatments. The competitor also claimed that a third party had misappropriated its trade secrets related to the patent involving ERAS-0015, and that Erasca is liable as a licensee under trade secret laws. Revolution Medicines has demanded that Erasca cease producing and selling ERAS-0015 in the United States.</p><p>While Erasca has stated it believes the assertions are without merit and intends to contest them vigorously, the allegations introduce significant uncertainty about the future of the company's key pipeline asset. The legal challenge overshadowed positive preliminary Phase 1 data that Erasca recently reported for ERAS-0015 in patients with RAS-mutant solid tumors, including lung and pancreatic cancer.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Erasca Plunges 30.08% in Overnight Trading Following Patent Infringement Allegations by Revolution Medicines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Erasca Plunges 30.08% in Overnight Trading Following Patent Infringement Allegations by Revolution Medicines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-28 15:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Erasca, Inc. (ERAS) experienced a dramatic 30.08% decline in overnight trading, as the clinical-stage oncology company faces serious legal challenges from competitor Revolution Medicines. The steep selloff was triggered by allegations that Erasca's development of its lead cancer drug, ERAS-0015, infringes on existing patents and relies on stolen trade secrets.</p><p>According to regulatory filings and news reports, Revolution Medicines sent Erasca a legal letter alleging that ERAS-0015 is \"substantially equivalent\" to one of its patented treatments. The competitor also claimed that a third party had misappropriated its trade secrets related to the patent involving ERAS-0015, and that Erasca is liable as a licensee under trade secret laws. Revolution Medicines has demanded that Erasca cease producing and selling ERAS-0015 in the United States.</p><p>While Erasca has stated it believes the assertions are without merit and intends to contest them vigorously, the allegations introduce significant uncertainty about the future of the company's key pipeline asset. The legal challenge overshadowed positive preliminary Phase 1 data that Erasca recently reported for ERAS-0015 in patients with RAS-mutant solid tumors, including lung and pancreatic cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ERAS","symbol_name":"Erasca, INC.","start_time":0,"source_url":"","article_id":"1177486383","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177486383","pubTimestamp":1777361703,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Erasca, Inc. (ERAS) experienced a dramatic 30.08% decline in overnight trading, as the clinical-stage oncology company faces serious legal challenges from competitor Revolution Medicines. The steep...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ERAS":"Erasca, INC."},"translate_title":"个股追踪|Revolution Medicines指控专利侵权后，Erasca隔夜暴跌30.08%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERAS":1},"content_text":"Erasca, Inc. (ERAS) experienced a dramatic 30.08% decline in overnight trading, as the clinical-stage oncology company faces serious legal challenges from competitor Revolution Medicines. The steep selloff was triggered by allegations that Erasca's development of its lead cancer drug, ERAS-0015, infringes on existing patents and relies on stolen trade secrets.According to regulatory filings and news reports, Revolution Medicines sent Erasca a legal letter alleging that ERAS-0015 is \"substantially equivalent\" to one of its patented treatments. The competitor also claimed that a third party had misappropriated its trade secrets related to the patent involving ERAS-0015, and that Erasca is liable as a licensee under trade secret laws. Revolution Medicines has demanded that Erasca cease producing and selling ERAS-0015 in the United States.While Erasca has stated it believes the assertions are without merit and intends to contest them vigorously, the allegations introduce significant uncertainty about the future of the company's key pipeline asset. The legal challenge overshadowed positive preliminary Phase 1 data that Erasca recently reported for ERAS-0015 in patients with RAS-mutant solid tumors, including lung and pancreatic cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}